Plan comparison
Plans, created in Eclipse and RefleXion X1 for each patient, were
evaluated for dose heterogeneity using dose to 2% of the PTV (D2%) and
mean dose to critical structures. The critical structures evaluated and
their dosimetric constraints are listed in Table 1. A paired sample
t-test was then performed to evaluate these dosimetric quantities
between the Eclipse and the RefleXion X1 plans for each patient, with
statistical significance defined at p<0.05.